Canada
· Delayed Price · Currency is CAD BriaCell Therapeutics Statistics
Total Valuation
TSX:BCT has a market cap or net worth of CAD 26.05 million. The enterprise value is 8.18 million.
| Market Cap | 26.05M |
| Enterprise Value | 8.18M |
Important Dates
The last earnings date was Monday, June 9, 2025.
| Earnings Date | Jun 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:BCT has 6.12 million shares outstanding. The number of shares has increased by 119.48% in one year.
| Current Share Class | 6.12M |
| Shares Outstanding | 6.12M |
| Shares Change (YoY) | +119.48% |
| Shares Change (QoQ) | +38.37% |
| Owned by Insiders (%) | 6.72% |
| Owned by Institutions (%) | 1.74% |
| Float | 5.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.30 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.24 |
Financial Position
The company has a current ratio of 3.41
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -660.34 |
Financial Efficiency
Return on equity (ROE) is -688.17% and return on invested capital (ROIC) is -534.73%.
| Return on Equity (ROE) | -688.17% |
| Return on Assets (ROA) | -131.54% |
| Return on Invested Capital (ROIC) | -534.73% |
| Return on Capital Employed (ROCE) | -192.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.68M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.22% in the last 52 weeks. The beta is 1.71, so TSX:BCT's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -82.22% |
| 50-Day Moving Average | 4.94 |
| 200-Day Moving Average | 9.87 |
| Relative Strength Index (RSI) | 40.67 |
| Average Volume (20 Days) | 7,261 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.74M |
| Pretax Income | -27.14M |
| Net Income | -26.86M |
| EBITDA | -33.53M |
| EBIT | -33.74M |
| Earnings Per Share (EPS) | -11.49 |
Balance Sheet
The company has 17.22 million in cash and n/a in debt, giving a net cash position of 17.22 million or 2.82 per share.
| Cash & Cash Equivalents | 17.22M |
| Total Debt | n/a |
| Net Cash | 17.22M |
| Net Cash Per Share | 2.82 |
| Equity (Book Value) | 16.50M |
| Book Value Per Share | 2.62 |
| Working Capital | 14.45M |
Cash Flow
In the last 12 months, operating cash flow was -33.27 million and capital expenditures -631,217, giving a free cash flow of -33.90 million.
| Operating Cash Flow | -33.27M |
| Capital Expenditures | -631,217 |
| Free Cash Flow | -33.90M |
| FCF Per Share | -5.54 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:BCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -119.48% |
| Shareholder Yield | n/a |
| Earnings Yield | -103.08% |
| FCF Yield | -130.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 29, 2025. It was a reverse split with a ratio of 0.0666667.
| Last Split Date | Jan 29, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |